51. 全身性強皮症 Disease details / Clinical trials / Drug dev / DR info

0,5 mg Prevenar i.m.
   Region Skane
      2011   -   NCT02240888   Sweden;
0,5 mg seasonal influenza vaccine i.m.
   Region Skane
      2011   -   NCT02240888   Sweden;
1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID
   Inventiva SA
      2017   Phase 2   EUCTR2015-001617-27-SI   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2017   Phase 2   EUCTR2015-001617-27-BG   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-DE   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
   Inventiva SAS
      2016   Phase 2   EUCTR2015-001617-27-NL   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-IT   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-ES   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;
1-22460
   ao. Univ. Prof. Dr. Elisabeth Aberer
      2006   Phase 4   EUCTR2006-000905-41-AT   Austria;
2 ml of whole blood sample will be collected on EDTA tube
   Assiut University
      2020   -   NCT04303208   -
2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt
   Vicore Pharma AB
      2019   Phase 2   EUCTR2019-003203-35-GB   United Kingdom;
A novel synthetic, orally-administered, non-peptide small molecule, which acts as an agonist of the melanocortin-1 receptor (MC1R)
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 2   EUCTR2020-000134-17-IT   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
ABR-215757
   Active Biotech AB
      2011   -   EUCTR2011-001667-44-SE   Germany;Sweden;Switzerland;
      2011   -   EUCTR2011-001667-44-DE   Germany;Sweden;Switzerland;
ACE-1334
   Acceleron Pharma Inc.
      2021   Phase 1/Phase 2   NCT04948554   United States;
ACHIM as solute (10^9 intestinal microbes/ml)
   Oslo University Hospital
      2020   Phase 2   NCT04300426   Norway;
ACT-064992
   ACTELION PHARMACEUTICALS LTD.
      2012   -   EUCTR2010-022710-77-IT   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;European Union;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
ACT-293987
   Actelion Pharmaceuticals Ltd
      2014   -   EUCTR2014-000865-34-GB   Germany;United Kingdom;
      2014   -   EUCTR2014-000865-34-DE   Germany;United Kingdom;
ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
ADSVF application in the right hand
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2015   Phase 2   NCT04387825   Mexico;
AIMSPRO
   Daval International Limited
      2008   Phase 2   EUCTR2007-003122-24-GB   United Kingdom;
AM-01
   Pharmarama International Limited
      2010   -   EUCTR2009-018194-31-GB   United Kingdom;
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
AUC of MPA measure
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04244916   France;
AVID200
   Formation Biologics
      2019   Phase 1   NCT03831438   United States;
Abatacept
   Dinesh Khanna, MD, MS
      2014   Phase 2   NCT02161406   Canada;United Kingdom;United States;
   Stanford University
      2008   Phase 1/Phase 2   NCT00442611   United States;
   University of Michigan
      2015   Phase 2   EUCTR2014-005323-27-GB   Canada;Italy;United Kingdom;United States;
Abituzumab
   EMD Serono Research & Development Institute, Inc.
      2016   Phase 2   NCT02745145   Argentina;Australia;Canada;Germany;Israel;Italy;Poland;Spain;Turkey;United Kingdom;United States;
   MERCK KGAA
      2016   Phase 2   EUCTR2015-005023-11-IT   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
Acetaminophen
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
Acetate
   Kuribayashi Shiko
      2020   -   JPRN-jRCTs031200019   Japan;
Acetylcysteine
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy;
Acetylsalicylic acid
   Federal University of São Paulo
      2018   Phase 4   NCT03558854   Brazil;
Acotiamide
   Juntendo University School of Medicine
      2018   -   JPRN-UMIN000031901   Japan;
Ad26.COV2.S
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Adempas
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Adipose tissue harvest
   University Hospital, Toulouse
      2020   Phase 2   NCT04356755   France;
Administration of rituximab and methylprednisolone
   University Hospital, Ghent
      2006   Phase 2   NCT00379431   Belgium;
Air filled balloon catheter
   University of Utah
      2004   Phase 4   NCT00204763   United States;
Albumin
   Daval International Limited
      2008   Phase 2   NCT00769028   United Kingdom;
Alemtuzumab
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
Alginic acid
   Khon Kaen University
      2013   Phase 3   NCT01878526   Thailand;
AlloRx
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05016804   Antigua and Barbuda;
Allogeneic Hematopoietic Stem Cell Transplantation
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States;
Allogeneic Mesenchymal Stem Cells (AlloMSC)
   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
      2009   Phase 1/Phase 2   NCT00962923   China;
Alpha-2C AR antagonist
   Orion Corporation Orion Pharma
      2011   -   EUCTR2010-024005-13-GB   United Kingdom;
Alprostadil
   NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
      2014   Phase 2   NCT02228850   United States;
Ambrisentan
   Heidelberg University
      2014   Phase 2   NCT02290613   Germany;
   National Jewish Health
      2012   -   NCT02169752   United States;
   Soumya Chatterjee
      2010   -   NCT01072669   United States;
   Stanford University
      2008   -   NCT00725361   United States;
   Thoraxklinik-Heidelberg gGmbH
      2014   Phase 2   EUCTR2014-001882-28-DE   Germany;
   University of California, Los Angeles
      2009   Phase 4   NCT01051960   United States;
   University of Pennsylvania
      2010   -   NCT01093885   United States;
Amlodipine Gel
   Pharmarama International Limited
      2010   -   EUCTR2009-018194-31-GB   United Kingdom;
Anaerobically Cultivated Human Intestinal Microbiota
   Oslo University Hospital
      2018   Phase 1/Phase 2   NCT03444220   Norway;
Anaerobically Cultivated medium
   Oslo University Hospital
      2018   Phase 1/Phase 2   NCT03444220   Norway;
Anti-CT51 antigen mAb
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
Anti-Thymocyte Globulin
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
Anti-Thymocyte Globulin, Rabbit
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Anti-integrin alphaV mAb
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
Anti-pandemic H1N1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil;
Anti-thymocyte globulin
   Fred Hutchinson Cancer Research Center
      2000   Phase 2   NCT00016458   United States;
Asasantin Retard ®
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom;
Aspirin
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom;
Assigned Interventions CD19/BCMA CAR T-cells
   Zhejiang University
      2021   Early Phase 1   NCT05085444   China;
Atorvastatin
   Robyn T. Domsic, MD, MPH
      2015   Phase 2   NCT02370784   United States;
Autologous ASC
   CHU de Toulouse
      2020   Phase 2   EUCTR2019-003906-28-FR   France;
   University Hospital, Toulouse
      2020   Phase 2   NCT04356755   France;
Autologous Hematopoietic Stem Cell Transplantation
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
Autologous Regulatory ?-cells
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2022   Phase 1/Phase 2   NCT05214014   -
Autologous Stem Cells
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
   University Hospital Tuebingen
      2012   Phase 2   NCT01895244   Germany;
Aviptadil
   MONDOGEN AG
      2008   -   EUCTR2007-003621-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
   MondoGEN AG
      2009   -   EUCTR2007-003621-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-003621-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
BAY63-2521
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
BH4
   VA Office of Research and Development
      2016   Phase 1/Phase 2   NCT02530996   United States;
BIBF 1120
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2018   Phase 3   EUCTR2016-003403-66-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim AB
      2018   Phase 3   EUCTR2016-003403-66-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim B.V
      2018   Phase 3   EUCTR2016-003403-66-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Ellas SA
      2015   Phase 3   EUCTR2015-000392-28-GR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim España, S.A.
      2015   Phase 3   EUCTR2015-000392-28-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Finland Ky
      2017   Phase 3   EUCTR2015-000392-28-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Fnland Ky
      2018   Phase 3   EUCTR2016-003403-66-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim France
      2015   Phase 3   EUCTR2015-000392-28-FR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2018   Phase 3   EUCTR2016-003403-66-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000392-28-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Norway KS
      2017   Phase 3   EUCTR2015-000392-28-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2015   Phase 3   EUCTR2015-000392-28-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2018   Phase 3   EUCTR2016-003403-66-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim bv
      2017   Phase 3   EUCTR2016-003403-66-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim España, S.A.
      2018   Phase 3   EUCTR2016-003403-66-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim France
      2018   Phase 3   EUCTR2016-003403-66-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim Pharma GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim RCV GmbH&Co KG
      2016   Phase 3   EUCTR2015-000392-28-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm. V
      2018   Phase 3   EUCTR2016-003403-66-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2016   Phase 3   EUCTR2015-000392-28-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
      2018   Phase 3   EUCTR2016-003403-66-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
BMS-986020
   Bristol-Myers Squibb
      2016   Phase 2   NCT02588625   Canada;France;Poland;United Kingdom;United States;
BNT162b2
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
BOSENTAN MONOHYDRATE
   University Medical Center Groningen (UMCG)
      2016   -   EUCTR2014-002796-28-NL   Netherlands;
BOTOX® solution
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03717961   France;
Baricitinib
   Huashan Hospital, Fudan University
      2021   Phase 0   ChiCTR2100041982   China;
Beam
   University Hospital, Strasbourg, France
      2015   -   NCT02371005   France;
Belimumab
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States;
      2012   Phase 2   NCT01670565   United States;
Belumosudil
   Kadmon Corporation, LLC
      2020   Phase 2   NCT04680975   United States;
Belumosudil (KD025)
   Kadmon Corporation, LLC
      2019   Phase 2   NCT03919799   United States;
Biopsy
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
   University Hospital, Bordeaux
      2012   -   NCT02562079   France;
Blood coagulation factor XIII
   University College London (UCL)
      2015   Phase 2   EUCTR2014-001101-40-GB   United Kingdom;
Blood sample
   University Hospital, Bordeaux
      2018   -   NCT03575156   France;
Blood samples
   Assistance Publique Hopitaux De Marseille
      2018   -   NCT03508375   France;
   University Hospital, Bordeaux
      2020   -   NCT04265144   France;
      2012   -   NCT02562079   France;
Blood sampling
   Medical University Innsbruck
      2019   -   NCT04095351   Austria;
Blood test
   University Hospital, Lille
      2021   -   NCT04746313   France;
Bone marrow transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
Bortezomib
   Northwestern University
      2016   Phase 2   NCT02370693   United States;
Bosentan
   ACTELION PHARMACEUTICALS ITALIA
      2005   -   EUCTR2004-000632-82-IT   Italy;
      2004   -   EUCTR2004-000631-28-IT   Italy;
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   Phase 3   EUCTR2010-021452-26-FR   France;
   Actelion
      2011   Phase 4   NCT01395732   Netherlands;
      2004   Phase 3   NCT00319696   Austria;Canada;France;Germany;Italy;Switzerland;United Kingdom;United States;
      2004   Phase 2/Phase 3   NCT00319033   Canada;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Sweden;Switzerland;United Kingdom;United States;
      2003   Phase 3   NCT02800993   Canada;United States;
      2003   Phase 3   NCT00077584   Canada;United States;
      2003   Phase 2/Phase 3   NCT00070590   France;Germany;Israel;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States;
   Actelion Pharmaceuticals Japan Ltd.
      2013   Phase 3   JPRN-JapicCTI-132176   -
   Actelion Pharmaceuticals Nederland bv
      2012   -   EUCTR2011-005303-32-NL   Netherlands;
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 2   NCT01241383   France;
   Georgetown University
      2006   Phase 2   NCT00377455   United States;
   Medical University of Graz
      2008   -   NCT00909337   Austria;
   Rikshospitalet University Hospital
      2005   Phase 1/Phase 2   NCT00226889   Norway;
   University College London
      2005   Phase 2   EUCTR2005-000701-61-GB   United Kingdom;
   University Medical Center Groningen
      2015   Phase 4   NCT02480335   Netherlands;
Bosentan (Tracleer)
   Heinrich-Heine University, Duesseldorf
      2006   Phase 2   NCT00318175   Germany;
Bosentan group
   Elpen Pharmaceutical Co. Inc.
      2016   -   NCT02798055   Greece;
Bosentan monohydrate
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom;
Botulinum toxin A
   Gunma University Hospital
      2014   -   JPRN-UMIN000017617   Japan;
Botulinum toxin type B
   Gunma University Hospital
      2016   -   JPRN-UMIN000024818   Japan;
Botulinum toxin type B (2500 units / vial)
   Gunma University
      2016   Phase 2   NCT03007004   Japan;
Botulinum toxin(Botox)
   University of Texas Southwestern Medical Center
      2020   Early Phase 1   NCT04523506   United States;
Brodalumab
   Kyowa Kirin Co., Ltd.
      2019   Phase 3   JPRN-JapicCTI-194761   Japan;
      2017   Phase 1   JPRN-JapicCTI-173686   Japan;
Bronchoalveolar lavage (BAL fluid)
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2021   -   NCT05007340   Canada;
Buspirone
   Laikon General District Hospital, Athens
      2014   Early Phase 1   NCT02363478   Greece;
Busulfan
   New York Medical College
      2007   Phase 1   NCT00684255   United States;
C-82 Topical Gel,
   Prism Pharma Co., Ltd.
      2015   Phase 1/Phase 2   NCT02349009   United States;
C21
   Vicore Pharma AB
      2020   Phase 2   NCT04388176   United Kingdom;
      2019   Phase 2   EUCTR2019-003203-35-GB   United Kingdom;
C225
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands;
CAM2043
   Camurus AB
      2020   Phase 2   EUCTR2019-002444-24-GB   United Kingdom;
CAPILLAREMA
   OSPEDALE MAGGIORE DI MILANO (IRCCS)
      2006   -   EUCTR2006-005230-20-IT   Italy;
CC-4047
   CELGENE CORPORATION
      2012   Phase 2   EUCTR2010-023047-15-IT   Australia;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-PL   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-023047-15-ES   Australia;France;Germany;Italy;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
CD34 selected autologous hematopoietic cells
   University Hospital Tuebingen
      2012   -   EUCTR2011-002434-40-DE   Germany;
CD34+SC
   University Hospital Tuebingen
      2012   -   EUCTR2011-002434-40-DE   Germany;
COVID-19 Vaccine (ChAdOx1-S [recombinant])
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA Vaccine (nucleoside modified)
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA vaccine (nucleoside-modified)
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA vaccine Moderna (CX-024414)
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 vaccine
   Paul R Fortin
      2022   Phase 2/Phase 3   NCT05236491   -
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
Calcipotriene
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
Calcium Channel Blockers
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Campath
   Children's Hospital Los Angeles
      2011   -   NCT01639573   United States;
   New York Medical College
      2007   Phase 1   NCT00684255   United States;
Cetuximab
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands;
Cialis
   University of Medicine and Dentistry of New Jersey
      2001   Phase 2   NCT00707187   United States;
Clobetasol
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
Comirnaty
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
Companion diagnostic ( CDx)
   Prometheus Biosciences, Inc.
      2022   Phase 2   NCT05270668   United States;
Cuprimine (penicillamine)
   Merck Sharp & Dohme Corp.
      2010   -   NCT01374282   -
Currently available therapy in the community
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   -   NCT00860548   United States;
Cutaneous iontophoresis of treprostinil
   University Hospital, Grenoble
      2012   Phase 1/Phase 2   NCT01554540   France;
Cyclophosphamide
   Akashi Koichi
      2019   Phase 2   JPRN-jRCTc071190041   Japan;
   Assistance Publique - Hôpitaux de Paris
      2013   Phase 3   NCT01570764   France;
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States;
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
      2000   Phase 2   NCT00016458   United States;
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
   Kyushu University
      2010   Phase 2   JPRN-UMIN000031940   Japan;
   Michael Roth
      2009   Phase 2   NCT00883129   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2/Phase 3   NCT00114530   Canada;United States;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom;
   The University of Texas Health Science Center, Houston
      1999   Phase 3   NCT00004563   -
   University of Manchester
      2010   -   NCT02339441   -
Cyclophosphamide Injection 1g
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
DI-17E6
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
DIGNA P144 CREAM
   ISDIN
      2007   Phase 2   EUCTR2007-002015-38-GB   Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002015-38-HU   Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002015-38-ES   Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002015-38-DE   Germany;Hungary;Italy;Spain;United Kingdom;
DIGNA P144 cream
   ISDIN
      2008   -   EUCTR2008-001265-28-HU   Germany;Hungary;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001265-28-GB   Germany;Hungary;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001265-28-ES   Germany;Hungary;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001265-28-DE   Germany;Hungary;Italy;Spain;United Kingdom;
Dabigatran etexilate
   Medical University of South Carolina
      2016   Phase 1   NCT02426229   United States;
Dasatinib
   Bristol-Myers Squibb
      2009   Phase 1/Phase 2   NCT00764309   United States;
Depletion of CD3/CD19 in an autologous stem cell transplant
   Stephan Grupp MD PhD
      2021   Phase 2   NCT05029336   United States;
Depot leuprolide acetate
   Joseph Mccune
      2011   Phase 3   NCT01257802   United States;
Dersimelagon
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 2   EUCTR2020-000134-17-IT   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2021   Phase 2   EUCTR2020-000134-17-DE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-000134-17-GB   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 2   EUCTR2020-000134-17-PL   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
Diltiazem Gel
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of;
Dimethyl Fumarate (DMF)
   Robert Lafyatis
      2016   Phase 1   NCT02981082   United States;
Diphenhydramine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
Dipyridamole
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom;
Divalproex sodium
   Yale University
      2014   Phase 1/Phase 2   NCT02166229   United States;
Domperidone
   Khon Kaen University
      2013   Phase 3   NCT01878526   Thailand;
Double-Blind Rituximab
   Tokyo University
      2017   Phase 2/Phase 3   NCT04274257   Japan;
Drug treatment
   Federal University of São Paulo
      2010   Phase 3   NCT01586663   Brazil;
Dupilumab
   University of Cologne
      2019   Phase 2   EUCTR2019-002036-90-DE   Germany;
Dupilumab 300Mg Solution for Injection
   University of Cologne
      2020   Phase 2   NCT04200755   Germany;
EMA/CHMP/212874/2015
   University Medial Center Groningen
      2018   Phase 4   EUCTR2018-001719-65-NL   Netherlands;
EMD 525797
   MERCK KGAA
      2016   Phase 2   EUCTR2015-005023-11-IT   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy;
ENDOPROST 0,05MG/0,5ML 1F
   ITALFARMACO
      2005   -   EUCTR2004-002712-28-IT   Italy;
ENDOPROST 50*INFUS 1F 0,050MG/
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy;
EX VIVO CULTURED HUMAN MESENCHYMAL STEM CELLS
   University Medical Center Utrecht
      2016   Phase 2   EUCTR2015-000168-32-NL   Netherlands;
Endoprost
   Azienda ospedaliera universitaria Ospedali Riuniti
      2014   Phase 2   EUCTR2013-004596-12-IT   Italy;
Endothelin receptor blocker
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Erbitux
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands;
Esbriet
   InterMune Inc.
      2013   -   EUCTR2013-001353-28-IT   Canada;Italy;United States;
Ethanol
   Indonesia University
      2016   -   NCT03141125   Indonesia;
FCR001
   Talaris Therapeutics Inc.
      2021   Phase 1/Phase 2   NCT05098145   United States;
FCX-013
   Castle Creek Biosciences, LLC.
      2019   Phase 1/Phase 2   NCT03740724   United States;
FT011
   Certa Therapeutics
      2021   Phase 2   NCT04647890   Australia;
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
Fasudil
   Johns Hopkins University
      2007   Phase 3   NCT00498615   United States;
Fibrogammin® 1250
   University College London (UCL)
      2015   Phase 2   EUCTR2014-001101-40-GB   United Kingdom;
Fibrogammin®P, coagulation factor XIII concentrate (Human)
   University College, London
      2015   Phase 2   NCT02551042   United Kingdom;
Filgrastim
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
   Northwestern University
      2011   Phase 3   NCT01445821   United States;
Fludarabine
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
   New York Medical College
      2007   Phase 1   NCT00684255   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
Fludarabine phosphate
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
Fractional carbon dioxide laser
   Cairo University
      2013   -   NCT02002897   Egypt;
Fresolimumab
   Boston University
      2011   Phase 1   NCT01284322   United States;
From August 2020 'no additional treatment'
   Prof. Ariane herrick
      2017   Phase 2   NCT03708718   United Kingdom;
G-CSF
   Akashi Koichi
      2019   Phase 2   JPRN-jRCTc071190041   Japan;
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
   Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
      2007   Phase 1,2   JPRN-UMIN000000589   Japan;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
G451990
   GALAPAGOS NV
      2019   Phase 2   EUCTR2019-001279-34-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States;
   Galapagos NV
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-ES   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-BE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
GLIVEC
   AZIENDA OSPEDALIERA S. CARLO
      2007   -   EUCTR2007-001508-19-IT   Italy;
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2007   -   EUCTR2007-005322-68-IT   Italy;
   NOVARTIS FARMA
      2008   -   EUCTR2007-004669-17-IT   Italy;United Kingdom;
GLPG1690
   GALAPAGOS NV
      2019   Phase 2   EUCTR2019-001279-34-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States;
   Galapagos NV
      2019   Phase 2   NCT03976648   Belgium;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   NCT03798366   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-ES   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-BE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
GM-CSF
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
GS-248
   Gesynta Pharma AB
      2020   Phase 2   NCT04744207   Belgium;Netherlands;Poland;United Kingdom;
      2020   Phase 2   EUCTR2020-002081-13-PL   Netherlands;Poland;United Kingdom;
      2020   Phase 2   EUCTR2020-002081-13-NL   Netherlands;Poland;United Kingdom;
      2020   Phase 2   EUCTR2020-002081-13-GB   United Kingdom;
      2019   Phase 1   NCT04036227   Sweden;
GSK2330811
   GlaxoSmithKline
      2017   Phase 2   NCT03041025   Canada;Netherlands;United Kingdom;United States;
      2015   Phase 1   NCT02386436   United Kingdom;
GSK2330811 Solution for Injection, 100mg/ml
   GlaxoSmithKline Research & Development Ltd
      2018   Phase 2   EUCTR2016-003417-95-NL   Canada;Netherlands;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003417-95-GB   Netherlands;United Kingdom;United States;
Glivec
   ErasmusMC
      2007   -   EUCTR2006-007091-15-NL   Netherlands;
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom;
Glivec 100 mg Filmtabletten
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom;
Glycyrrhizin
   Sumida Hayakazu
      2020   -   JPRN-jRCTs031180366   Japan;
Gran
   Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
      2007   Phase 1,2   JPRN-UMIN000000589   Japan;
Guselkumab
   Numaguchi Hirotaka
      2021   Phase 2   JPRN-jRCT2051200133   Japan;
Guselkumab Dose 1
   Janssen Pharmaceutical K.K.
      2021   Phase 2   NCT04683029   Japan;
Guselkumab Dose 2
   Janssen Pharmaceutical K.K.
      2021   Phase 2   NCT04683029   Japan;
HIDONAC*EV 1FL 5G 25ML
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy;
HZN-825
   HORIZON THERAPEUTICS IRELAND DAC
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-IT   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
   Horizon Therapeutics Ireland DAC
      2022   Phase 2   EUCTR2020-005764-62-PL   Argentina;Austria;Belgium;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 2   EUCTR2020-005764-62-NL   Argentina;Austria;Belgium;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-PT   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-ES   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005764-62-GR   Argentina;Austria;Belgium;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005764-62-DE   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005764-62-AT   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
HZN-825 BID
   Horizon Therapeutics Ireland DAC
      2021   Phase 2   NCT04781543   Argentina;France;Greece;Korea, Republic of;Portugal;United States;
HZN-825 QD
   Horizon Therapeutics Ireland DAC
      2021   Phase 2   NCT04781543   Argentina;France;Greece;Korea, Republic of;Portugal;United States;
Hematopoietic stem cell transplantation
   Richard Burt, MD
      2005   Phase 1   NCT00282425   United States;
High-dose intravenous immunoglobulin (Venoglobulin-IH)
   Benesis Corporation
      2006   Phase 3   NCT00348296   Japan;
Hizentra
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
   Genzyme, a Sanofi Company
      2002   Phase 1/Phase 2   NCT00043706   United States;
Human normal immunoglobulin for intravenous (IV) administration
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
Human normal immunoglobulin for intravenous administration
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
Human normal immunoglobulin for subcutaneous administration
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
Hyaluronidase injected intradermally
   Brigham and Women's Hospital
      2020   Early Phase 1   NCT04656704   -
Hyperimmune caprine serum
   Daval International Limited
      2008   Phase 2   NCT00769028   United Kingdom;
Hyperoxia
   University of British Columbia
      2022   -   NCT03800017   -
ILOPROST SALE DI TROMETAMOLO
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy;
ILOPROST TROMETAMOL
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy;
IMATINIB MESILATO
   NOVARTIS FARMA
      2008   -   EUCTR2007-004669-17-IT   Italy;United Kingdom;
IMMUNOGLOBULINA UMANA NORMALE
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
INCB039110
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2020   Phase 2   EUCTR2019-003430-16-FR   France;
INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 1/Phase 2   NCT02213705   France;
IS (B cell depletion therapy)
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IS (MMF or MPA)
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IS (MTX)
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IV Cyclophosphamide
   Johns Hopkins University
      2001   Phase 3   NCT00501995   United States;
IVA337
   Inventiva Pharma
      2015   Phase 2   NCT02503644   Bulgaria;France;Germany;Italy;Netherlands;Poland;Slovenia;Spain;Switzerland;United Kingdom;
   Inventiva SA
      2017   Phase 2   EUCTR2015-001617-27-SI   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2017   Phase 2   EUCTR2015-001617-27-BG   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-GB   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-DE   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
   Inventiva SAS
      2016   Phase 2   EUCTR2015-001617-27-NL   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-IT   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-ES   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;
IVIg
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
Idrossiclorochina solfato
   UMBERTO I - POLICLINICO DI ROMA
      2022   Phase 3   EUCTR2021-000230-33-IT   Italy;
IgPro10
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring
      2019   Phase 2   NCT04138485   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   NCT04137224   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
IgPro20
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring
      2019   Phase 2   NCT04137224   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
Iguratimod
   RenJi Hospital
      2021   -   NCT04515706   -
Ilomedin
   ao. Univ. Prof. Dr. Elisabeth Aberer
      2006   Phase 4   EUCTR2006-000905-41-AT   Austria;
Iloprost
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy;
   National Center for Research Resources (NCRR)
      1995   Phase 3   NCT00004786   -
Iloprost Injection, for intravenous use
   Eicos Sciences, Inc.
      2019   Phase 3   NCT04040322   United States;
      2019   Phase 2   NCT03867097   United States;
Iloprost low dose
   Charite University, Berlin, Germany
      1997   Phase 2   NCT00622687   Germany;
Iloprost therapy up to 2 ng/kg x min
   Charite University, Berlin, Germany
      1997   Phase 2   NCT00622687   Germany;
Iloprost trometamol
   ITALFARMACO
      2005   -   EUCTR2004-002712-28-IT   Italy;
Imatinib
   AZIENDA OSPEDALIERA S. CARLO
      2007   -   EUCTR2007-001508-19-IT   Italy;
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2007   -   EUCTR2007-005322-68-IT   Italy;
   Azienda Ospedaliera Universitaria Policlinico
      2009   Phase 2   NCT00573326   Italy;
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom;
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom;
   University of California, Los Angeles
      2007   Phase 1/Phase 2   NCT00512902   United States;
Imatinib Mesylate
   Hospital for Special Surgery, New York
      2007   Phase 2   NCT00555581   United States;
Imatinib mesylate
   Lawson Health Research Institute
      2008   Phase 2   NCT01545427   Canada;
   Lee, Stephanie
      2011   Phase 2   NCT01309997   United States;
   Stanford University
      2007   Phase 1/Phase 2   NCT00506831   United States;
   University Hospital, Bordeaux
      2007   Phase 2   NCT00479934   France;
Imiquimod cream
   The Hospital for Sick Children
      2005   Phase 3   NCT00147771   Canada;
Immunoglobulina Normale Umana per somministrazione endovenosa
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
Immunoglobulina Normale Umana per somministrazione sottocutanea
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
Immunoglobulina normale umana per somministrazione endovenosa
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
Imnovid 1 mg hard capsules
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-GB   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-023047-15-DE   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Inebilizumab
   Kondou Kazuoki
      2022   Phase 3   JPRN-jRCT2031210521   Japan;
   Mitsubishi Tanabe Pharma Corporation
      2022   Phase 3   NCT05198557   Japan;
Influenza vaccine
   Tel-Aviv Sourasky Medical Center
      2009   Phase 4   NCT01002508   Israel;
Injection of autologous stromal vascular fraction
   The Catholic University of Korea
      2016   -   NCT02975960   Korea, Republic of;
Intravenous immunoglobulin
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
Iontophoresis of treprostinil
   University Hospital, Grenoble
      2017   Phase 1/Phase 2   NCT03120533   France;
Itacitinib
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT04789850   France;
Ixazomib
   W. Leroy Griffing
      2021   Phase 2   NCT04837131   United States;
JBT-101
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-PL   Australia;Austria;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 2   NCT02465437   United States;
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-NL   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000372-29-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-000372-29-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
KHK4827
   Kyowa Kirin Co., Ltd.
      2019   Phase 3   NCT03957681   Japan;
      2019   Phase 3   JPRN-JapicCTI-194761   Japan;
      2017   Phase 1   NCT04368403   Japan;
      2017   Phase 1   JPRN-JapicCTI-173686   Japan;
Lactobacillus
   University of Michigan
      2012   Phase 4   NCT01497743   United States;
Lenabasum
   Corbus Pharmaceuticals Inc.
      2017   Phase 3   NCT03398837   Australia;Canada;Germany;Israel;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Lenabasum 20 mg Powder in Capsule
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Lenabasum 5 mg Powder in Capsule
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Lenabasum 5mg Powder in Capsule
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Leukapheresis
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
Leukopheresis
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
Lidocaine without vessel constrictor
   Federal University of São Paulo
      2004   Phase 2/Phase 3   NCT00740285   Brazil;
Lipitor
   Salford Royal Hospitals NHS Trust
      2008   Phase 4   EUCTR2005-003775-21-GB   United Kingdom;
Liposomal bupivacaine
   Jose Soberon, MD
      2014   Phase 2/Phase 3   NCT02374320   United States;
MABp1 (Bermekimab)
   Hellenic Institute for the Study of Sepsis
      2019   Phase 2   NCT04045743   Greece;
MEDI-546
   MedImmune LLC
      2009   Phase 1   NCT00930683   United States;
MEDI-551
   MedImmune LLC
      2010   Phase 1   NCT00946699   Canada;United Kingdom;United States;
METHYLPREDNISOLONE SODIUM SUCCINATE
   Radboudumc
      2019   Phase 4   EUCTR2015-004613-24-BE   Belgium;Netherlands;
      2016   Phase 4   EUCTR2015-004613-24-NL   Netherlands;
METOCLOPRAMIDE ACCORD - 10 MG COMPRESSE 28 COMPRESSE IN BLISTER PVC/PVDC/AL
   MEDAC GMBH
      2016   Phase 3   EUCTR2015-002586-39-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
MHSCT
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2/Phase 3   NCT00114530   Canada;United States;
MMF
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States;
MPA
   Region Skane
      2018   -   NCT03678987   Sweden;
MQX-503
   MediQuest Therapeutics
      2006   Phase 2   NCT00378521   United States;
   MediQuest Therapeutics, Inc.
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom;
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom;
MSC
   University Medical Center Utrecht
      2016   Phase 2   EUCTR2015-000168-32-NL   Netherlands;
MT-7117
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 2   EUCTR2020-000134-17-IT   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2021   Phase 2   EUCTR2020-000134-17-DE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-000134-17-GB   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America, Inc.
      2021   Phase 2   NCT04440592   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 2   EUCTR2020-000134-17-PL   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
MabThera
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
   University Hospital Gent
      2006   -   EUCTR2006-003836-31-BE   Belgium;
Macitentan
   ACTELION PHARMACEUTICALS LTD.
      2012   -   EUCTR2010-022710-77-IT   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;European Union;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
   Actelion
      2011   Phase 3   NCT01474122   Argentina;Belgium;China;Colombia;Germany;Greece;Ireland;Israel;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   NCT01474109   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
   Actelion Pharmaceuticals Ltd
      2014   -   EUCTR2010-022710-77-CZ   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United Kingdom;
      2012   Phase 3   EUCTR2010-022969-95-BE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022969-95-PT   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022969-95-PL   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022969-95-NL   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022969-95-GR   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022710-77-PL   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2012   -   EUCTR2010-022710-77-FI   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2011   Phase 3   EUCTR2010-022969-95-GB   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022969-95-IE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022969-95-ES   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022969-95-DE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022710-77-HU   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2011   -   EUCTR2010-022710-77-DK   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2011   -   EUCTR2010-022710-77-DE   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2011   -   EUCTR2010-022710-77-BG   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
Manual toothbrush and water flosser (Philips Sonicare AirFloss)
   University Hospital, Strasbourg, France
      2021   -   NCT04627857   France;
Measurment with Aspirational Medical Device
   Oliver Distler
      2018   -   NCT03644225   Switzerland;
Measurment with Cutometer MPA 580
   Oliver Distler
      2018   -   NCT03644225   Switzerland;
Mesenchymal Stem Cells from Wharton ´s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ´s jelly
   Universidad de la Sabana
      2022   -   NCT04432545   Colombia;
Mesna
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
Methotrexate
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2020   Phase 0   ChiCTR2000031572   China;
   University of California, Los Angeles
      2002   Phase 1/Phase 2   NCT00241189   United States;
   University of Manchester
      2010   -   NCT02339441   -
Methoxsalen
   Lawson Health Research Institute
      2022   Phase 2   NCT04986605   Canada;
Methylprednisolon
   Radboudumc
      2019   Phase 4   EUCTR2015-004613-24-BE   Belgium;Netherlands;
      2016   Phase 4   EUCTR2015-004613-24-NL   Netherlands;
Methylprednisolone
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
   Radboud University
      2017   Early Phase 1   NCT03059979   Netherlands;
Methylprednisolone acetate
   Assiut University
      2018   -   NCT03742466   Egypt;
Metronidazole
   Coordinación de Investigación en Salud, Mexico
      2015   Phase 4   NCT03692299   Mexico;
Microgynon
   Boehringer Ingelheim
      2018   Phase 1   NCT03675581   Belgium;France;Germany;Netherlands;Portugal;Spain;
Mizoribine
   Faculty of Life Sciences, Kumamoto University
      2010   -   JPRN-UMIN000004162   Japan;
Moderna mRNA-1273
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Mycophenolate Mofetil (MMF)
   Michael Roth
      2017   Phase 2   NCT03221257   United States;
Mycophenolate mofetil
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
   Michael Roth
      2009   Phase 2   NCT00883129   United States;
   Northwestern University
      2016   Phase 2   NCT02370693   United States;
   Postgraduate Institute of Medical Education and Research
      2016   Phase 3   NCT02896205   India;
   UMC Utrecht
      2020   Phase 4   EUCTR2019-004718-32-NL   Netherlands;
   University of California, San Francisco
      2006   -   NCT00333437   United States;
   University of Manchester
      2010   -   NCT02339441   -
Mycophenolic acid
   Region Skane
      2018   -   NCT03678987   Sweden;
N-acetylcysteine (NAC)
   Università Politecnica delle Marche
      2007   Phase 2/Phase 3   NCT00428883   Italy;
NON PROPIETRY, THEREFORE N/A
   Salford Royal Hospitals Trust
      2007   Phase 2   EUCTR2004-002799-41-GB   United Kingdom;
Nemolizumab
   Maruho Co., Ltd.
      2022   Phase 2   NCT05214794   Japan;
   Nishiura Tomoyuki
      2021   Phase 2   JPRN-jRCT2031210481   Japan;
Neovasculgen
   Human Stem Cell Institute, Russia
      2015   Phase 1/Phase 2   NCT02356809   Russian Federation;
Neupogen
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Nilotinib (Tasigna)
   Hospital for Special Surgery, New York
      2010   Phase 2   NCT01166139   United States;
Nintedanib
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim
      2020   -   NCT04325217   Japan;
      2018   Phase 1   NCT03675581   Belgium;France;Germany;Netherlands;Portugal;Spain;
      2017   Phase 3   NCT03313180   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   NCT02597933   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Nitroglycerin
   MediQuest Therapeutics
      2007   Phase 3   NCT00577304   United States;
Nitroglycerin Ointment
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of;
Nitroglycerine gel
   MediQuest Therapeutics, Inc.
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom;
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom;
Nitroglycerine in Propylene Glycol, USP
   MediQuest Therapeutics, Inc.
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom;
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom;
Nivolumab
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States;
Non applicabile
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2016   Phase 2   EUCTR2016-001028-80-IT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
None yet
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
ORM-12471
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01315899   United Kingdom;
ORM-12741
   Orion Corporation Orion Pharma
      2011   -   EUCTR2010-024005-13-GB   United Kingdom;
Ofev
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2018   Phase 3   EUCTR2016-003403-66-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim AB
      2018   Phase 3   EUCTR2016-003403-66-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim B.V
      2018   Phase 3   EUCTR2016-003403-66-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Ellas SA
      2015   Phase 3   EUCTR2015-000392-28-GR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim España, S.A.
      2015   Phase 3   EUCTR2015-000392-28-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Finland Ky
      2017   Phase 3   EUCTR2015-000392-28-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Fnland Ky
      2018   Phase 3   EUCTR2016-003403-66-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim France
      2015   Phase 3   EUCTR2015-000392-28-FR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2018   Phase 3   EUCTR2016-003403-66-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000392-28-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Norway KS
      2017   Phase 3   EUCTR2015-000392-28-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2015   Phase 3   EUCTR2015-000392-28-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2018   Phase 3   EUCTR2016-003403-66-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim bv
      2017   Phase 3   EUCTR2016-003403-66-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim España, S.A.
      2018   Phase 3   EUCTR2016-003403-66-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim France
      2018   Phase 3   EUCTR2016-003403-66-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim Pharma GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim RCV GmbH&Co KG
      2016   Phase 3   EUCTR2015-000392-28-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm. V
      2018   Phase 3   EUCTR2016-003403-66-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2016   Phase 3   EUCTR2015-000392-28-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
      2018   Phase 3   EUCTR2016-003403-66-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Omeprazole
   Khon Kaen University
      2013   Phase 1   NCT03561233   -
Onabotulinumtoxin A
   Johns Hopkins University
      2015   Phase 3   NCT02165111   United States;
Ophthalmic Emulsion
   Allergan
      2001   Phase 3   NCT00025818   United States;
Opsumit 10 Mg Tablet
   Franz Rischard, DO
      2018   Phase 2/Phase 3   NCT03726398   United States;
Oral Ifetroban
   Cumberland Pharmaceuticals
      2017   Phase 2   NCT02682511   India;United States;
Oral bovine type I collagen
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2000   Phase 2   NCT00005675   United States;
Oral treprostinil
   Stanford University
      2016   Phase 2   NCT02663895   United States;
Order of two elements of surgical procedure
   Duke University
      2017   Phase 4   NCT03155464   -
Other vasodilator
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Ozone
   Assiut University
      2018   -   NCT03742466   Egypt;
   Pamukkale University
      2021   -   NCT04826419   Turkey;
P144
   ISDIN
      2007   Phase 2   NCT00574613   Germany;Hungary;Italy;Poland;Spain;United Kingdom;
   ISDIN S.A.
      2009   -   EUCTR2007-002015-38-IT   Germany;Hungary;Italy;Spain;United Kingdom;
P144 Cytokine Inhibitor
   ISDIN
      2008   -   EUCTR2008-001265-28-DE   Germany;Hungary;Italy;Spain;United Kingdom;
P144 Cytokines Inhibitors
   ISDIN
      2008   -   EUCTR2008-001265-28-HU   Germany;Hungary;Italy;Spain;United Kingdom;
   ISDIN S.A.
      2010   -   EUCTR2008-001265-28-IT   Germany;Hungary;Italy;Spain;United Kingdom;
P144 DIGNA CREAM
   ISDIN
      2007   Phase 2   EUCTR2007-002015-38-GB   Germany;Hungary;Italy;Spain;United Kingdom;
P144 cream
   ISDIN
      2008   Phase 2   NCT00781053   Germany;Hungary;Italy;Poland;Spain;United Kingdom;
P144. Cytokines Inhibitors
   ISDIN
      2008   -   EUCTR2008-001265-28-GB   Germany;Hungary;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001265-28-ES   Germany;Hungary;Italy;Spain;United Kingdom;
   ISDIN S.A.
      2010   -   EUCTR2008-001265-28-IT   Germany;Hungary;Italy;Spain;United Kingdom;
PLACENTEX ® Polydeoxyribonucleotide
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy;
PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy;
PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy;
POLYDEOXYRIBONUCLEOTIDES
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy;
PR1
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany;
PRA023 IV
   Prometheus Biosciences, Inc.
      2022   Phase 2   NCT05270668   United States;
PRIVIGEN - 100 MG/ML - SOLUZIONE PER INFUSIONE USO ENDOVENOSO FLACONCINO(VETRO) 1 FLACONCINO DA 100 ML
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
PRUCALOPRIDE SUCCINATE
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2013   -   EUCTR2012-005348-92-IT   Italy;
Paquinimod
   Active Biotech AB
      2011   Phase 2   NCT01487551   Germany;Sweden;Switzerland;
      2011   -   EUCTR2011-001667-44-SE   Germany;Sweden;Switzerland;
      2011   -   EUCTR2011-001667-44-DE   Germany;Sweden;Switzerland;
Part B Open-Label Extension
   Corbus Pharmaceuticals Inc.
      2015   Phase 2   NCT02465437   United States;
Patients will be randomized to receive EHP-101
   Emerald Health Pharmaceuticals
      2020   Phase 2   NCT04166552   Australia;New Zealand;United States;
Peripheral Blood Stem Cell Transplantation
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
Peripheral Blood Stem Cells
   Northwestern University
      2011   Phase 3   NCT01445821   United States;
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
Phosphodiesterase Inhibitors
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Physiological saline
   Gunma University
      2016   Phase 2   NCT03007004   Japan;
Pirfenidone
   Beijing Continent Pharmaceutical Co, Ltd.
      2018   Phase 3   NCT03856853   China;
   Genentech, Inc.
      2013   Phase 2   NCT01933334   Canada;Italy;United States;
   RenJi Hospital
      2017   Phase 2/Phase 3   NCT03068234   China;
Pirfenidone (PFD)
   Michael Roth
      2017   Phase 2   NCT03221257   United States;
Placebo
   Chugai Pharmaceutical Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-152963   Japan, North America, Europe, 25 countries including Japan, US, UK, Germany etc.;
   Kyowa Kirin Co., Ltd.
      2019   Phase 3   JPRN-JapicCTI-194761   Japan;
Platelet Gel
   Università Politecnica delle Marche
      2007   Phase 2/Phase 3   NCT00463125   Italy;
Plerixafor
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
Polydeoxyribonucleotides
   Mastelli S.r.l
      2016   Phase 4   NCT03388255   Italy;
Pomalidomida
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-ES   Australia;France;Germany;Italy;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Pomalidomide
   CELGENE CORPORATION
      2012   Phase 2   EUCTR2010-023047-15-IT   Australia;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-PL   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-023047-15-GB   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-023047-15-DE   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Pomalidomide (CC-4047)
   Celgene
      2012   Phase 2   NCT01559129   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Prednisolon
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisolona
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisolone
   Prof. Ariane herrick
      2017   Phase 2   NCT03708718   United Kingdom;
Prednisolone 5mg Gastro-resistant Tablets
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisolone and taper
   Khon Kaen University
      2018   Phase 2   NCT03607071   Thailand;
Prednisoloni
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisolonum
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisone
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
Prednizolon
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednizolonas
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Privigen
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
   Georgetown University
      2013   -   NCT01785056   United States;
Prostanoids
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Pyrophosphate
   Szeged University
      2021   -   NCT04966416   -
QAX576
   Novartis Pharmaceuticals
      2007   Phase 2   NCT00581997   United States;
Quality-of-life assessment
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
RATG
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
RESOLOR*28CPR RIV
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2013   -   EUCTR2012-005348-92-IT   Italy;
RO487-7533/F10-04
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 3   EUCTR2015-000424-28-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-000424-28-IE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000424-28-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-LT   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-HR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 3   EUCTR2015-000424-28-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
Rabeprazole
   Faculty of Medicine,Institute of Medical, Pharmaceutical and Health Sciences,Kanazawa University
      2005   -   JPRN-UMIN000020701   Japan;
Rapamycin
   University of California, Los Angeles
      2002   Phase 1/Phase 2   NCT00241189   United States;
RbATG
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Recombinant humanized anti-human monoclonal antibody directed against the IL-6R
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States;
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States;
Reduced Intensity Allogeneic Transplant
   New York Medical College
      2007   Phase 1   NCT00684255   United States;
Reduced intensity allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
Relaxin
   National Center for Research Resources (NCRR)
      1991   Phase 2   NCT00004380   -
   University of Medicine and Dentistry of New Jersey
      1998   Phase 3   NCT00704665   -
Resunab, ajulemic acid, anabasum
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-PL   Australia;Austria;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-NL   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000372-29-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-000372-29-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Rilonacept
   Boston University
      2011   Phase 1/Phase 2   NCT01538719   United States;
Ringer lactate
   Assistance Publique Hopitaux De Marseille
      2017   Phase 2   NCT02866552   France;
      2015   Phase 2   NCT02558543   France;
Riocigu
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Riociguat
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Dinesh Khanna, MD, MS
      2016   Phase 2   NCT02915835   United States;
Riociguat (Adempas, BAY63-2521)
   Bayer
      2015   Phase 2   NCT02283762   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
Riociguat coated tablet
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Riociguat coated tablet 2.5 m
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
Rituximab
   Assistance Publique - Hôpitaux de Paris
      2013   Phase 2/Phase 3   NCT01748084   France;
   Department of Dermatology, University of Tokyo
      2012   -   JPRN-UMIN000007702   Japan;
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States;
   LUMC
      2009   -   EUCTR2008-007180-16-NL   Netherlands;
   Lee, Stephanie
      2011   Phase 2   NCT01309997   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom;
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
   University Hospital Gent
      2006   -   EUCTR2006-003836-31-BE   Belgium;
   University Hospital, Ghent
      2009   Phase 2   NCT00936546   Belgium;
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan;
   Yoshizaki Ayumi
      2012   Phase 2   JPRN-jRCTs031180373   Japan;
Ro 47-0203
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom;
Ro 487-7533/F10-04
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States;
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States;
Ro47-0203 / ACT-050088
   Actelion Pharmaceuticals Japan Ltd.
      2013   Phase 3   JPRN-JapicCTI-132176   -
RoActemra
   F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-000424-28-IE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000424-28-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-LT   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-HR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States;
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States;
Rosemary
   ARCIM Institute Academic Research in Complementary and Integrative Medicine
      2015   -   NCT03531216   Germany;
Rosuvastatin
   Faculty of Medicine, University of Alexandria
      2008   Phase 3   NCT00984932   Egypt;
SAR100842
   SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT
      2013   -   EUCTR2012-001369-34-IT   Canada;Germany;Italy;Switzerland;United Kingdom;United States;
   Sanofi
      2013   Phase 2   NCT01651143   France;Germany;Italy;Switzerland;United Kingdom;United States;
   Sanofi-aventis recherche & développement
      2012   Phase 2   EUCTR2012-001369-34-GB   Canada;Germany;Italy;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2012-001369-34-DE   Canada;Germany;Switzerland;United Kingdom;United States;
SAR156597
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2016   Phase 2   EUCTR2016-001028-80-IT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
   Sanofi
      2016   Phase 2   NCT02921971   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
   sanofi-aventis recherche & développement
      2016   Phase 2   EUCTR2016-001028-80-EE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001028-80-DE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001028-80-BE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001028-80-AT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;United Kingdom;United States;
SAR231893
   University of Cologne
      2019   Phase 2   EUCTR2019-002036-90-DE   Germany;
SINVACOR*28CPR RIV
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-006035-32-IT   Italy;
SODIUM NITROPRUSSIDE
   Salford Royal Hospitals Trust
      2007   Phase 2   EUCTR2004-002799-41-GB   United Kingdom;
SODIUM THIOSULFATE PENTAHYDRATE
   CHU de LIMOGES
      2019   Phase 2   EUCTR2018-001978-22-FR   France;
STI571
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom;
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom;
   Novartis Pharmaceuticals
      2008   Phase 2   NCT00613171   Germany;Italy;Switzerland;United Kingdom;United States;
STS
   University Hospital, Limoges
      2020   Phase 2   NCT03582800   France;
Saccharomyces Boulardii Oral Tablet
   Coordinación de Investigación en Salud, Mexico
      2015   Phase 4   NCT03692299   Mexico;
Selexipag
   Actelion
      2014   Phase 2   NCT02260557   France;Germany;United Kingdom;
Self bone marrow transplant
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
Serial night time position splint
   Federal University of São Paulo
      2010   Phase 3   NCT01586663   Brazil;
Sildenafil
   Johns Hopkins University
      2021   Phase 2   NCT04797286   United States;
   University Hospital, Lille
      2010   Phase 3   NCT01295736   France;
Sildenafil 20mg and Bosentan
   Postgraduate Institute of Medical Education and Research
      2016   Phase 4   NCT03053739   India;
Sildenafil citrate
   Federal University of São Paulo
      2011   Phase 3   NCT01347008   Brazil;
Sildenafil therapy
   Charite University, Berlin, Germany
      2004   Phase 2   NCT00624273   Germany;
Simvastatin
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-006035-32-IT   Italy;
Sirolimus
   Peking University People's Hospital
      2018   Phase 2   NCT03365869   -
   The First Affiliated Hospital of China Medical University
      2020   Phase 0   ChiCTR2000030370   China;
Sodium chloride
   Radboud University
      2017   Early Phase 1   NCT03059979   Netherlands;
Sodium fluoride 18F
   University Medial Center Groningen
      2018   Phase 4   EUCTR2018-001719-65-NL   Netherlands;
Solid state catheter
   University of Utah
      2004   Phase 4   NCT00204763   United States;
Solu-Medrone
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Solu-medrone
   Newcastle upon Tyne NHS Foundation Trust
      2008   Phase 4   EUCTR2008-000224-27-GB   United Kingdom;
Soluble Ve cadherin
   University Hospital, Grenoble
      2014   -   NCT02212249   France;
Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)
   University Hospital, Strasbourg, France
      2021   -   NCT04627857   France;
Standard of care
   Northwestern University
      2005   Phase 2   NCT00278525   United States;
Stem cell transplantation
   Northwestern University
      2005   Phase 2   NCT00278525   United States;
Sterile saline solution
   Johns Hopkins University
      2015   Phase 3   NCT02165111   United States;
Steroids
   RenJi Hospital
      2017   Phase 2/Phase 3   NCT03068234   China;
Stromal Vascular fraction
   Assistance Publique Hopitaux De Marseille
      2017   Phase 2   NCT02866552   France;
      2015   Phase 2   NCT02558543   France;
Study of the gene expression profile
   Assistance Publique Hopitaux De Marseille
      2018   -   NCT03629002   France;
TERGURIDE HYDROGENMALEATE
   MEDAC GMBH
      2016   Phase 3   EUCTR2015-002586-39-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
   medac GmbH
      2017   Phase 3   EUCTR2015-002586-39-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-PT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-GB   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-FR   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
TRACLEER*125MG 56CPR RIV.
   ACTELION PHARMACEUTICALS ITALIA
      2004   -   EUCTR2004-000631-28-IT   Italy;
TRACLEER*56CPR RIV
   ACTELION PHARMACEUTICALS ITALIA
      2005   -   EUCTR2004-000632-82-IT   Italy;
Tacrolimus
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
   The First Affiliated Hospital of Guangzhou University of Chinese Medicine
      2021   Phase 0   ChiCTR2100042327   China;
Tadalafil
   Sanjay Gandhi Postgraduate Institute of Medical Sciences
      2012   Phase 3   NCT01553981   India;
      2009   Phase 3   NCT01117298   India;
      2007   Phase 3   NCT00626665   -
Tadalafil and ambrisentan upfront combination therapy
   Johns Hopkins University
      2010   Phase 4   NCT01042158   United States;
Temanogrel
   Arena Pharmaceuticals
      2021   Phase 2   NCT04915950   United Kingdom;United States;
Terguride
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany;
Thalidomide
   New York University School of Medicine
      2000   Phase 1   NCT00418132   United States;
The ozone generator device (Human Pro medic, German)
   Assiut University
      2016   -   NCT02733978   -
Thiotepa
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
Thymoglobulin
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
Thymoglobuline
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Tocilizumab
   CHUGAI PHARMACEUTICAL CO., LTD
      2017   Phase 3   JPRN-JapicCTI-173760   Japan;
   Chugai Pharmaceutical Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-152963   Japan, North America, Europe, 25 countries including Japan, US, UK, Germany etc.;
   Hoffmann-La Roche
      2015   Phase 3   NCT02453256   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
   Kanazawa University Hospital
      2016   -   JPRN-UMIN000022624   Japan;
   Kanazawa University Hospital, Department of dermatology
      2015   -   JPRN-UMIN000020389   Japan;
   Osaka University
      2014   -   JPRN-UMIN000015495   Japan;
   Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine
      2011   Phase 2   JPRN-UMIN000005550   Japan;
   The University of Tokyo
      2013   -   JPRN-UMIN000012214   Japan;
   Yoshizaki Ayumi
      2013   Phase 2   JPRN-jRCTs031180370   Japan;
Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS)
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States;
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States;
Tocilizumab [RoActemra/Actemra]
   Hoffmann-La Roche
      2012   Phase 3   NCT01532869   Canada;France;Germany;United Kingdom;United States;
Tofacitinib
   University of Michigan
      2017   Phase 1/Phase 2   NCT03274076   United States;
Topical AmphiMatrix
   MediQuest Therapeutics
      2007   Phase 3   NCT00577304   United States;
Topical AmphiMatrix with nitroglycerin (MQX-503)
   MediQuest Therapeutics
      2006   Phase 3   NCT00419419   Sweden;United Kingdom;United States;
Topical calcipotriene ointment
   Northwestern University
      2015   -   NCT02411643   United States;
Topical organogel with nitroglycerin
   MediQuest Therapeutics
      2004   Phase 2/Phase 3   NCT00253331   United States;
Total Body Irradiation
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
Total-Body Irradiation
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States;
Tracleer
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   Phase 3   EUCTR2010-021452-26-FR   France;
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom;
   Actelion Pharmaceuticals Nederland bv
      2012   -   EUCTR2011-005303-32-NL   Netherlands;
   University College London
      2005   Phase 2   EUCTR2005-000701-61-GB   United Kingdom;
   University Medical Center Groningen (UMCG)
      2016   -   EUCTR2014-002796-28-NL   Netherlands;
Transdihydrolisuride
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany;
Treprostinil diethanolamine
   United Therapeutics
      2009   Phase 2   NCT00848107   Canada;United Kingdom;United States;
      2009   Phase 2   NCT00775463   Canada;United Kingdom;United States;
      2008   Phase 1   NCT00848939   United States;
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States;
      2009   -   EUCTR2008-005018-39-GB   United Kingdom;
Trimebutine
   Third Department of Internal Medicine (Department of Rheumatology) Shimane University Faculty of Medicine
      2017   Phase 3   JPRN-UMIN000026859   Japan;
UCMSC
   Marie Hudson, MD
      2022   Phase 1/Phase 2   NCT04356287   -
UT-15 SR
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States;
UT-15C SR
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States;
      2009   -   EUCTR2008-005018-39-GB   United Kingdom;
UT-15C-SR
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States;
      2009   -   EUCTR2008-005018-39-GB   United Kingdom;
Ultraviolet A1 phototherapy (UVA1)
   Cairo University
      2013   -   NCT02002897   Egypt;
Urine sample
   University Hospital, Bordeaux
      2018   -   NCT03575156   France;
VIB7734
   Viela Bio
      2018   Phase 1   NCT03817424   Poland;Spain;United States;
VIP
   MONDOGEN AG
      2008   -   EUCTR2007-003621-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
   MondoGEN AG
      2009   -   EUCTR2007-003621-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-003621-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Vaseline
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of;
Veledimex
   Castle Creek Biosciences, LLC.
      2019   Phase 1/Phase 2   NCT03740724   United States;
Vitamin D3
   Coordinación de Investigación en Salud, Mexico
      2017   -   NCT04822038   Mexico;
Vivomixx probiotics
   Singapore General Hospital
      2013   Phase 2   NCT01804959   Singapore;
Volibris
   Thoraxklinik-Heidelberg gGmbH
      2014   Phase 2   EUCTR2014-001882-28-DE   Germany;
Yellow Fever vaccine (17D)
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil;
ZD4054
   University College London
      2014   Phase 2   EUCTR2013-003200-39-GB   United Kingdom;
Zibotentan
   University College London
      2014   Phase 2   EUCTR2013-003200-39-GB   United Kingdom;
   University College, London
      2014   Phase 2   NCT02047708   United Kingdom;
Ziritaxestat
   Galapagos NV
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;